Phenylalanine hydroxylase gene therapy
Alternative Names: Phenylalanine hydroxylase gene therapy - Castle Creek PharmaceuticalsLatest Information Update: 06 Feb 2022
At a glance
- Originator Castle Creek Pharmaceuticals
- Class Fibroblast cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Phenylketonuria
Most Recent Events
- 25 Jan 2022 Early research in Phenylketonuria in USA (Parenteral) (Castle Creek Pharmaceuticals pipeline, January 2022)